Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Cheng‐Ta Yang(Shanghai Medical College of Fudan University), Nobuyuki Yamamoto(Wakayama Medical University), Jin‐Hyoung Kang(The Catholic University of Korea Seoul St. Mary's Hospital), Hye Ryun Kim(Yonsei University), K.H. Lee(Chungbuk National University Hospital), Takamasa Yoshida, J.-S. Lee(Seoul National University Bundang Hospital), Makoto Nishio(Japanese Foundation For Cancer Research), Hiroaki Akamatsu(Army Medical University), Toyoaki Hida(Saitama International Medical Center), Yuichiro Ohe(National Cancer Center), Hiroshi Tanaka(Tokyo Medical and Dental University), Tomohide Tamura(St. Luke's International Hospital), Yoshinobu Namba(Ono Pharmaceutical (Japan)), Naoki Inui(Hamamatsu University School of Medicine), Naoki Sumiyoshi(Ono Pharmaceutical (Japan)), Chong‐Jen Yu(National Taiwan University Hospital)
Cited by 202
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k